Sanofi: Sarclisa Approved in The U.S. As The First Anti-CD38 Therapy in Combination With Standard-of-Care Treatment for Adult Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
September 21, 2024
September 21, 2024
PARIS, France, Sept. 21 (TNSres) -- Sanofi, a life sciences company, issued the following news release:
* * *
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
- Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) s . . .
* * *
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
- Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) s . . .